Robin I. Mcconnell
Kincraig, SCT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 25, 2026
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 11, 2024
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 14, 2022
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Journal: The New England journal of medicine
Published: June 03, 2021
Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer.
Journal: Anti-cancer drugs
Published: July 16, 2019
Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
Journal: Cancer chemotherapy and pharmacology
Published: October 22, 2018
The Use of Biochip Array Technology for Rapid Multimycotoxin Screening.
Journal: Journal of AOAC International
Published: July 27, 2016
Development of an Evidence biochip array kit for the multiplex screening of more than 20 anthelmintic drugs.
Journal: Analytical and bioanalytical chemistry
Published: December 14, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026